14 GHP Q3 2023 s the first and only UK company that is currently able to boast an innovative drug repositioning and repurposing technology platform, with this system having resulted in the successful development of a range of preventative pharmaceutical products designed to reduce some of the adverse effects of cancer treatment, VasoDynamics Ltd (VDL) is in the development process of a range of pioneering products for use both before and after cancer treatment. Focusing on the key areas of hair, mouth, and skin, as demonstrated above, Founder and CEO Dr Ningfeng Fiona Li is at the helm of this most noble operation, which strives to benefit the lives of those all over the world who are facing unimaginable hardship. Presently, one of the clinical trials that is ongoing for the company is its NG11-2 mouthwash medicine, with this product having been designed to prevent severe mouth ulcers in those patients Feb24404 A Established in 2020, VasoDynamics Ltd is a biopharmaceutical company that is based in England and specialises in the development of a series of cost-effective, patient-friendly, and preventative therapies that are designed to reduce, or prevent, some of the more common complications that stem from cancer treatment. Whether it be hair loss, painful mouth ulcers, or radiodermatitis, the side effects of treatment for this horrific disease can severely impact a person’s confidence and health, and the overall efficacy of the control on cancer disease. With products from this company, however, not only can a patient experience an improved quality of life, but improved tolerability to repeated cancer treatment, improved life journey living with cancer for long term and reduced healthcare burden caused by the sideeffects. Founder and CEO Dr Ningfeng Fiona Li is on hand for more. who are currently undergoing chemotherapy or radiotherapy for head and neck cancers. Fiona tells us, “VDL’s current NG11-2 Phase Ib trial has successfully completed the dose escalation phase and is initiating the dose-expansion phase. […] The initial clinical readout is promising, and VDL’s abstract [has been] accepted by the European Society of Radiotherapy and Oncology (ESTRO) 2024 Annual Congress, and [it] will be presenting the clinical readouts in the conference in Glasgow in May.” Beyond this, Fiona is also pleased to announce that the team have secured follow-up funding for an optimisation to their innovative NG13 drug, an advanced offering that can prevent hair-loss induced by chemotherapy, with this set to be ready to enter Phase II trials sometime over the next two years. These are just some examples of the pioneering work that is being carried out, a duty that, for Fiona, represents the future of preventative treatment. She explains, “the existing products are symptomatic control, wound dressing, pain control, and treatment for secondary infections. There is a clearly underserved, unmet need for an effective, preventive, and patient-friendly medicine to reduce/prevent these debilitating and traumatising side effects.” Utilising its aforementioned state-of-the-art drug repositioning and repurposing technology to appease this very need, all of the technologies and products used by VDL are patent protected and adhere strictly to all of the policies of the market, including data confidentially. Leveraging such technologies, Fiona and her team are highly experienced, diversified, and passionate, with these experts having either been through or witnessed for themselves the debilitating side effects that many cancer treatments and therapies can have. On the back of this, the team are steadfast in their support for others, determined to minimise their burdens. With such togetherness to boot, Fiona describes the collaborative culture that has arisen as a result as having, “enabled the team to function as a whole to move the development of a complex of technologies and products into clinics in a cost- […] and timeefficient manner.” In a similar vein, when Fiona and her team are seeking out new members for their team, one of the first things that candidates are asked about is what their understanding is of cancer patients’ unmet needs, this in addition to them having to state what they believe they can bring to the table to remedy this, before speaking with other members of the team to ensure that they fit in seamlessly. This wholly united team are all looking forward to an exciting rest of the year for VasoDynamics Ltd, confident that the upcoming phases of the clinical trials that are set to take place later this year will lead to the promising results that we are all hoping for. No matter what the future holds for Dr Ningfeng Fiona Li and her team, their dedication to managing the cancer treatment side effects for patients through preventative, patient-friendly solutions remains unwavering, and we wish this team nothing less than the best of luck as they continue to pioneer in this space. Contact: Dr Ningfeng Fiona Li Email: [email protected] Company: VasoDynamics Ltd Web Address: https://vasodynamics.co.uk/ Best Cancer Care Solutions Provider 2024 - UK
RkJQdWJsaXNoZXIy MTUyMDQwMA==